Balyasny Asset Management
BMRN icon

Balyasny Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Balyasny Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,800
Closed -$560K – 2753
2024
Q2 		$560K Buy
+6,800
New +$566K ﹤0.01% 2021

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's BMRN Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 1,362,752 shares worth $77M. The stake represents 0.1% of the portfolio and ranks #227 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in BMRN as recently as Q3 2025.

Balyasny Asset Management first reported a position in BMRN in Q2 2014 and has held it in 41 quarters since. The position peaked at $156M in Q4 2017. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Balyasny Asset Management held 1,362,752 shares of BioMarin Pharmaceuticals worth $77M as of Q1 2026.
  • BioMarin Pharmaceuticals was a new Balyasny Asset Management position in Q1 2026.
  • BioMarin Pharmaceuticals made up 0.1% of Balyasny Asset Management's portfolio in Q1 2026, its #227 holding.
  • Balyasny Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 41 quarters since.
  • Balyasny Asset Management's BioMarin Pharmaceuticals position peaked at $156M in Q4 2017.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.